Item request has been placed!

Item request cannot be made.

Processing Request

Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy

Item request has been placed!

Item request cannot be made.

Processing Request

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

المؤلفون: Jaroslav Zivny; William Selove; Lacey J. McIntosh; Jan Cerny; Xin Wang
المصدر:
Leukemia & Lymphoma. 62:2022-2025
الموضوع:
Oncology; Cancer Research; medicine.medical_specialty; Immunoconjugates; Salvage therapy; 03 medical and health sciences; 0302 clinical medicine; Refractory; immune system diseases; hemic and lymphatic diseases; Internal medicine; Antineoplastic Combined Chemotherapy Protocols; medicine; Humans; neoplasms; Pseudoprogression; Salvage Therapy; business.industry; Antibodies, Monoclonal; Hematology; medicine.disease; Polatuzumab vedotin; Lymphoma; 030220 oncology & carcinogenesis; Lymphoma, Large B-Cell, Diffuse; business; Diffuse large B-cell lymphoma; 030215 immunology
الدخول الالكتروني :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d4c16a7a0d994e5f038013da56e2f3
https://doi.org/10.1080/10428194.2021.1894646

معلومة اضافية
- بيانات النشر:
  Informa UK Limited, 2021.
- الموضوع:
  2021
- نبذة مختصرة :
  Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25% of non-Hodgkin lymphoma cases [1]. Although often treatment-responsive, 30–40% of DLBCL patients develop refractory or relapsed ...
- ISSN:
  1029-2403
  1042-8194
- الرقم المعرف:
  10.1080/10428194.2021.1894646
- الرقم المعرف:
  edsair.doi.dedup.....45d4c16a7a0d994e5f038013da56e2f3

تعليقات

No Comments.